Calliditas Therapeutics announces full FDA approval of TARPEYO, the only FDA-approved treatment for IgA nephropathy to significantly reduce the loss of kidney function Read more
FDA grants priority review to Xolair (omalizumab) for children and adults with food allergies based on positive National Institutes of Health phase III study results Read more
FDA Grants Priority Review to Merck’s New Biologics License Application for V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed to Protect Adults Read more
Gilead and Compugen Announce Exclusive License Agreement for Novel Pre-Clinical Immunotherapy Program Read more
Teva and Biolojic Design Announce Exclusive License Agreement for the Development of a Therapeutic Antibody for Atopic Dermatitis and Asthma Read more
Kyverna Therapeutics Granted FDA Fast Track Designation for KYV-101 in the Treatment of Patients With Refractory Myasthenia Gravis Read more
FDA Grants Priority Review to Amgen’s Tarlatamab Application for Advanced Small Cell Lung Cancer Read more